Gerlies Treiber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gerlies Treiber has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Rudolf Pieber
Division of Endocrinology and Diabetology, Department of Internal Medicine Medical University of Graz Graz Austria
4 shared publications - Angelika Lang
Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, 8036 Graz, Austria
2 shared publications - Armin Zittermann
Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum Nordrhein Westfalen, Ruhr University Bochum, Bad Oeynhausen, Germany
2 shared publications - Barbara Obermayer-Pietsch
Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
2 shared publications - Barbara Prietl
Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria
2 shared publications - Christian Trummer
Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
2 shared publications
Latest Publications
- Open Access
- 23 October 2024
- Published by Springer Nature in Journal für Endokrinologie, Diabetologie und Stoffwechsel
- Vol. 17 (4) , 126-131
Diabetologische Notfälle: hyperglykämische Krisen
Zusammenfassung: Die diabetische Ketoazidose (DKA) und das hyperglykämische hyperosmolare Syndrom (HHS) sind die zwei schwerwiegendsten, akut lebensbedrohlichen hyperglykämischen Notfälle in Patient*innen mit Diabetes Typ 1 und Diabetes Typ 2. Weltweit zeigt sich in den letzten 10 Jahren eine Zunahme der stationären Aufnahmen aufgrund dieser hyperglykämischen Krisen. Die DKA ist gekennzeichnet durch eine Hyperglykämie, Ketonämie sowie metabolische Azidose mit erhöhter Anionenlücke, während es beim HHS zu einer ausgeprägten Hyperglykämie, Hyperosmolarität und Dehydration ohne Azidose kommt. Die frühzeitige Diagnose und die Kenntnisse der Therapiemodalitäten sind notwendig, um Komplikationen zu vermeiden. Die Therapiesäulen beruhen auf dem Flüssigkeitsersatz, Insulintherapie und Elektrolytausgleich sowie der Behandlung der auslösenden Ursache. Ohne eine entsprechende Behandlung sind hyperglykämischen Krisen mit einer erheblichen, wenn auch weitgehend vermeidbaren Morbidität und Mortalität verbunden. Die Verwendung von DKA-/HHS-Protokollen in den Krankenhäusern ist zu empfehlen. Wiederholte Schulungen der Patient*innen sowie der behandelnden Teams inklusive der „sick day rules“ sind in der Prävention und Therapie der hyperglykämischen Krisen entscheidend.
- 23 October 2024
- Published by Springer Nature in Journal für Endokrinologie, Diabetologie und Stoffwechsel
- Vol. 17 (4) , 126-131
Open AccessDiabetologische Notfälle: hyperglykämische Krisen
Zusammenfassung: Die diabetische Ketoazidose (DKA) und das hyperglykämische hyperosmolare Syndrom (HHS) sind die zwei schwerwiegendsten, akut lebensbedrohlichen hyperglykämischen Notfälle in Patient*innen mit Diabetes Typ 1 und Diabetes Typ 2. Weltweit zeigt sich in den letzten 10 Jahren eine Zunahme der stationären Aufnahmen aufgrund dieser hyperglykämischen Krisen. Die DKA ist gekennzeichnet durch eine Hyperglykämie, Ketonämie sowie metabolische Azidose mit erhöhter Anionenlücke, während es beim HHS zu einer ausgeprägten Hyperglykämie, Hyperosmolarität und Dehydration ohne Azidose kommt. Die frühzeitige Diagnose und die Kenntnisse der Therapiemodalitäten sind notwendig, um Komplikationen zu vermeiden. Die Therapiesäulen beruhen auf dem Flüssigkeitsersatz, Insulintherapie und Elektrolytausgleich sowie der Behandlung der auslösenden Ursache. Ohne eine entsprechende Behandlung sind hyperglykämischen Krisen mit einer erheblichen, wenn auch weitgehend vermeidbaren Morbidität und Mortalität verbunden. Die Verwendung von DKA-/HHS-Protokollen in den Krankenhäusern ist zu empfehlen. Wiederholte Schulungen der Patient*innen sowie der behandelnden Teams inklusive der „sick day rules“ sind in der Prävention und Therapie der hyperglykämischen Krisen entscheidend.
- Open Access
Differences in Hemodynamic, Hormonal and Heart Rate Variability Parameters in Complication-Free Pregnancies Compared to Individuals with Gestational Diabetes Mellitus and Preeclampsia: An Observational Retrospective Analysis
To investigate differences in hemodynamic, hormonal and heart rate variability parameters in women following complication-free pregnancies (healthy), preeclampsia and gestational diabetes mellitus (GDM) after giving childbirth. Data of 60 women (healthy: n = 29, age 32.7 ± 4.5 years, BMI 24.2 ± 4.3 kg/m2; preeclampsia: n = 16, age 35.3 ± 4.4 years, 28.5 ± 6.4 kg/m2; GDM, n = 15, age 32.3 ± 6.0 years, BMI 26.4 ± 6.2 kg/m2) were included. Two visits were conducted 16 and 48 weeks after giving childbirth. Hair samples were taken for analysis of cortisol and testosterone. ECG and blood pressure were recorded at each visit. Data were analyzed via RM-ANOVA and post-hoc testing (p ≤ 0.05). Heart rate increased from visit 1 to visit 2, whereas SDNN decreased (both p = 0.03). RMSSD showed an increased trend for groups (p = 0.06). Testosterone in the GDM group was significantly higher compared to the other groups (p = 0.002). Cortisol levels were significantly higher following post-hoc testing GDM was different compared to healthy individuals (p = 0.02). Hemodynamic changes from week 16 to week 48 did not differ between groups (p > 0.05). No differences between individuals with preeclampsia and healthy individuals were found for all hemodynamic parameters (p > 0.05). The study showed higher levels of chronic stress indicators in GDM measured via heart rate variability and cortisol compared to women with a history of preeclampsia and healthy women.
Open AccessDifferences in Hemodynamic, Hormonal and Heart Rate Variability Parameters in Complication-Free Pregnancies Compared to Individuals with Gestational Diabetes Mellitus and Preeclampsia: An Observational Retrospective Analysis
To investigate differences in hemodynamic, hormonal and heart rate variability parameters in women following complication-free pregnancies (healthy), preeclampsia and gestational diabetes mellitus (GDM) after giving childbirth. Data of 60 women (healthy: n = 29, age 32.7 ± 4.5 years, BMI 24.2 ± 4.3 kg/m2; preeclampsia: n = 16, age 35.3 ± 4.4 years, 28.5 ± 6.4 kg/m2; GDM, n = 15, age 32.3 ± 6.0 years, BMI 26.4 ± 6.2 kg/m2) were included. Two visits were conducted 16 and 48 weeks after giving childbirth. Hair samples were taken for analysis of cortisol and testosterone. ECG and blood pressure were recorded at each visit. Data were analyzed via RM-ANOVA and post-hoc testing (p ≤ 0.05). Heart rate increased from visit 1 to visit 2, whereas SDNN decreased (both p = 0.03). RMSSD showed an increased trend for groups (p = 0.06). Testosterone in the GDM group was significantly higher compared to the other groups (p = 0.002). Cortisol levels were significantly higher following post-hoc testing GDM was different compared to healthy individuals (p = 0.02). Hemodynamic changes from week 16 to week 48 did not differ between groups (p > 0.05). No differences between individuals with preeclampsia and healthy individuals were found for all hemodynamic parameters (p > 0.05). The study showed higher levels of chronic stress indicators in GDM measured via heart rate variability and cortisol compared to women with a history of preeclampsia and healthy women.
- Open Access
- 6 November 2020
- Published by Springer Nature in Journal für Klinische Endokrinologie und Stoffwechsel
- Vol. 13 (4) , 177-181
Nicht-Diabetes-assoziierte Hypoglykämien
Zusammenfassung: Die Symptome einer Hypoglykämie sind häufig und unspezifisch. Echte Hypoglykämien sind selten und kommen meistens im Rahmen einer Insulintherapie vor. Die Diagnose einer Hypoglykämie bei Patienten ohne Diabetes erfordert das Vorliegen der Whipple-Trias mit dokumentierter Blutglukose ≤ 55 mg/dl, hypoglykämischen Symptomen und deren Verschwinden durch Zufuhr von Kohlenhydraten. Eine weitere Abklärung erfolgt mittels standardisiertem 72‑h Fastentest oder bei Patienten mit vorwiegend postprandialen Hypoglykämien einem 5‑h-Mahlzeitentoleranztest. Die parallele Messung von Plasmaglukose, Insulin, C‑Peptid, Proinsulin und Ketonen hilft in der Differenzierung zwischen Insulinom, faktitieller Gabe von Insulin und Sulfonylharnstoffen sowie Nesidioblastose (NIPHS) und Hypoglykämien nach bariatrischen Operationen. Die Messung von Insulin-Autoantikörpern ist hinweisend auf ein autoimmunes Insulinsyndrom und der Nachweis von „big“ IFG‑2 auf eine paraneoplastische Sekretion dieses Proteins bei Tumorerkrankungen. Erst wenn der Nachweis einer autonomen endogenen Hyperinsulinämie vorliegt, erfolgt die Lokalisationsdiagnostik. Dabei sind szintigrafische Untersuchungen mittels radioaktivem 68Gallium und Exendin‑4 und ein selektiver Kalzium-Stimulationstest in der Lokalisation von Insulinomen hilfreich. Therapeutisch ist eine Hypoglykämie akut durch Glukosegabe zu behandeln. Die langfristige Therapie besteht wenn möglich in der Beseitigung der auslösenden Ursache, Ernährungsmaßnahmen sowie medikamentöser Hemmung der Insulinsekretion.
- 6 November 2020
- Published by Springer Nature in Journal für Klinische Endokrinologie und Stoffwechsel
- Vol. 13 (4) , 177-181
Open AccessNicht-Diabetes-assoziierte Hypoglykämien
Zusammenfassung: Die Symptome einer Hypoglykämie sind häufig und unspezifisch. Echte Hypoglykämien sind selten und kommen meistens im Rahmen einer Insulintherapie vor. Die Diagnose einer Hypoglykämie bei Patienten ohne Diabetes erfordert das Vorliegen der Whipple-Trias mit dokumentierter Blutglukose ≤ 55 mg/dl, hypoglykämischen Symptomen und deren Verschwinden durch Zufuhr von Kohlenhydraten. Eine weitere Abklärung erfolgt mittels standardisiertem 72‑h Fastentest oder bei Patienten mit vorwiegend postprandialen Hypoglykämien einem 5‑h-Mahlzeitentoleranztest. Die parallele Messung von Plasmaglukose, Insulin, C‑Peptid, Proinsulin und Ketonen hilft in der Differenzierung zwischen Insulinom, faktitieller Gabe von Insulin und Sulfonylharnstoffen sowie Nesidioblastose (NIPHS) und Hypoglykämien nach bariatrischen Operationen. Die Messung von Insulin-Autoantikörpern ist hinweisend auf ein autoimmunes Insulinsyndrom und der Nachweis von „big“ IFG‑2 auf eine paraneoplastische Sekretion dieses Proteins bei Tumorerkrankungen. Erst wenn der Nachweis einer autonomen endogenen Hyperinsulinämie vorliegt, erfolgt die Lokalisationsdiagnostik. Dabei sind szintigrafische Untersuchungen mittels radioaktivem 68Gallium und Exendin‑4 und ein selektiver Kalzium-Stimulationstest in der Lokalisation von Insulinomen hilfreich. Therapeutisch ist eine Hypoglykämie akut durch Glukosegabe zu behandeln. Die langfristige Therapie besteht wenn möglich in der Beseitigung der auslösenden Ursache, Ernährungsmaßnahmen sowie medikamentöser Hemmung der Insulinsekretion.
- Open Access
Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial
Increasing evidence suggests a possible interaction between vitamin D and insulin-like growth factor-1 (IGF-1). We aimed to investigate effects of vitamin D supplementation on IGF-1 (primary outcome) and calcitriol (1,25(OH)2D) concentrations (secondary outcome). This is a post-hoc analysis of the Styrian Vitamin D Hypertension Trial—a single-center, double-blind, randomized, placebo-controlled trial (RCT) conducted from 2011 to 2014 at the Medical University of Graz, Austria. Two-hundred subjects with arterial hypertension and 25(OH)D concentrations 2D (r = 0.21; p = 0.005) but not with 25(OH)D (r = −0.008; p = 0.91). In the RCT, vitamin D had no significant effect on IGF-1 (mean treatment effect 3.1; 95% confidence interval −5.6 to 11.9 ng/mL; p = 0.48), but it increased 1,25(OH)2D concentrations (mean treatment effect 9.2; 95% confidence interval 4.4 to 13.9 pg/mL; p ≤ 0.001). In this RCT, in hypertensive patients with low 25(OH)D concentrations, there was no significant effect of vitamin D supplementation on IGF-1 concentrations. However, we observed a cross-sectional correlation between 1,25(OH)2D and IGF-1 and an increase of 1,25(OH)2D after vitamin D supplementation.
Open AccessEffects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial
Increasing evidence suggests a possible interaction between vitamin D and insulin-like growth factor-1 (IGF-1). We aimed to investigate effects of vitamin D supplementation on IGF-1 (primary outcome) and calcitriol (1,25(OH)2D) concentrations (secondary outcome). This is a post-hoc analysis of the Styrian Vitamin D Hypertension Trial—a single-center, double-blind, randomized, placebo-controlled trial (RCT) conducted from 2011 to 2014 at the Medical University of Graz, Austria. Two-hundred subjects with arterial hypertension and 25(OH)D concentrations 2D (r = 0.21; p = 0.005) but not with 25(OH)D (r = −0.008; p = 0.91). In the RCT, vitamin D had no significant effect on IGF-1 (mean treatment effect 3.1; 95% confidence interval −5.6 to 11.9 ng/mL; p = 0.48), but it increased 1,25(OH)2D concentrations (mean treatment effect 9.2; 95% confidence interval 4.4 to 13.9 pg/mL; p ≤ 0.001). In this RCT, in hypertensive patients with low 25(OH)D concentrations, there was no significant effect of vitamin D supplementation on IGF-1 concentrations. However, we observed a cross-sectional correlation between 1,25(OH)2D and IGF-1 and an increase of 1,25(OH)2D after vitamin D supplementation.
- Open Access
Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial
Bone turnover markers (BTMs) are used to evaluate bone health together with bone mineral density and fracture assessment. Vitamin D supplementation is widely used to prevent and treat musculoskeletal diseases but existing data on vitamin D effects on markers of bone resorption and formation are inconsistent. We therefore examined the effects of vitamin D supplementation on bone-specific alkaline phosphatase (bALP), osteocalcin (OC), C-terminal telopeptide (CTX), and procollagen type 1 N-terminal propeptide (P1NP). This is a post-hoc analysis of the Styrian Vitamin D Hypertension Trial, a single-center, double-blind, randomized, placebo-controlled trial (RCT) performed at the Medical University of Graz, Austria (2011–2014). Two hundred individuals with arterial hypertension and 25-hydroxyvitamin D (25[OH]D) levels p = 0.533), CTX (MTE 0.024, 95% CI −0.163 to 0.210 ng/mL, p = 0.802), OC (MTE 0.020, 95% CI −0.062 to 0.103 ng/mL, p = 0.626), or P1NP (MTE −0.021, 95% CI −0.099 to 0.057 ng/mL, p = 0.597). Analyzing patients with 25(OH)D levels n = 74) left results largely unchanged. In hypertensive patients with low 25(OH)D levels, we observed no significant effect of vitamin D supplementation for eight weeks on BTMs.
Open AccessEffects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial
Bone turnover markers (BTMs) are used to evaluate bone health together with bone mineral density and fracture assessment. Vitamin D supplementation is widely used to prevent and treat musculoskeletal diseases but existing data on vitamin D effects on markers of bone resorption and formation are inconsistent. We therefore examined the effects of vitamin D supplementation on bone-specific alkaline phosphatase (bALP), osteocalcin (OC), C-terminal telopeptide (CTX), and procollagen type 1 N-terminal propeptide (P1NP). This is a post-hoc analysis of the Styrian Vitamin D Hypertension Trial, a single-center, double-blind, randomized, placebo-controlled trial (RCT) performed at the Medical University of Graz, Austria (2011–2014). Two hundred individuals with arterial hypertension and 25-hydroxyvitamin D (25[OH]D) levels p = 0.533), CTX (MTE 0.024, 95% CI −0.163 to 0.210 ng/mL, p = 0.802), OC (MTE 0.020, 95% CI −0.062 to 0.103 ng/mL, p = 0.626), or P1NP (MTE −0.021, 95% CI −0.099 to 0.057 ng/mL, p = 0.597). Analyzing patients with 25(OH)D levels n = 74) left results largely unchanged. In hypertensive patients with low 25(OH)D levels, we observed no significant effect of vitamin D supplementation for eight weeks on BTMs.
- 1 December 2015
- Published by Elsevier in Clinical Immunology
- Vol. 161 (2) , 217-224
Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus — A randomized clinical trial
- 1 December 2015
- Published by Elsevier in Clinical Immunology
- Vol. 161 (2) , 217-224
Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus — A randomized clinical trial
- Top Cited PapersOpen Access
Vitamin D and Immune Function
Vitamin D metabolizing enzymes and vitamin D receptors are present in many cell types including various immune cells such as antigen-presenting-cells, T cells, B cells and monocytes. In vitro data show that, in addition to modulating innate immune cells, vitamin D also promotes a more tolerogenic immunological status. In vivo data from animals and from human vitamin D supplementation studies have shown beneficial effects of vitamin D on immune function, in particular in the context of autoimmunity. In this review, currently available data are summarized to give an overview of the effects of vitamin D on the immune system in general and on the regulation of inflammatory responses, as well as regulatory mechanisms connected to autoimmune diseases particularly in type 1 diabetes mellitus.
Top Cited PapersOpen AccessVitamin D and Immune Function
Vitamin D metabolizing enzymes and vitamin D receptors are present in many cell types including various immune cells such as antigen-presenting-cells, T cells, B cells and monocytes. In vitro data show that, in addition to modulating innate immune cells, vitamin D also promotes a more tolerogenic immunological status. In vivo data from animals and from human vitamin D supplementation studies have shown beneficial effects of vitamin D on immune function, in particular in the context of autoimmunity. In this review, currently available data are summarized to give an overview of the effects of vitamin D on the immune system in general and on the regulation of inflammatory responses, as well as regulatory mechanisms connected to autoimmune diseases particularly in type 1 diabetes mellitus.